GLOW for Eyes: What the Evidence Shows
What human and animal studies show about GLOW for eyes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- from an ingredient's studies
- Human studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 4
- with an outcome for eyes
Evidence for eyes
Each row is an outcome related to eyes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here. No study has tested GLOW itself; rows are for each ingredient.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| TB-500: Ocular discomfort and corneal staining | At day 56, the treated group had a 35.1% greater reduction in ocular discomfort and a 59.1% greater reduction in total corneal fluorescein staining than vehicle (very small trial). | Human RCTn = 9 | Cornea 2015, PMID 25826322 |
| TB-500: Primary endpoints | Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly between groups. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Secondary endpoints | Discomfort scores in the challenge environment on day 28 were 27% lower than placebo (P=0.0244), a secondary endpoint. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Corneal alkali burn | The peptide-containing hydrogel accelerated corneal epithelial regeneration and reduced inflammation in an alkali burn model; this is a formulation study. | Animal · human corneal cells in vitro plus an animal alkali burn model (species not stated in abstract) (not a human result) | ACS applied materials & interfaces 2025, PMID 41359360 |
| BPC-157: Intraocular pressure | All BPC 157 regimens (eye drops, intraperitoneal, oral) normalized intraocular pressure in this rat glaucoma model. | Animal · rat (not a human result) | Biomedicines 2021, PMID 35052769 |
GLOW and eyes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What eye care covers
MedlinePlus frames eye care as daily habits, regular checkups and treatment when needed.[5]
Eye studies, one component at a time
In a rat model of open-angle glaucoma, BPC-157 given as eye drops, by injection into the abdomen or in drinking water was reported to normalise eye pressure (an animal study of one GLOW component).[4]
In cell cultures, a hydrogel built around the TB500 sequence promoted human corneal epithelial cell migration, proliferation and tight junction recovery; this was a lab study of a gel, not an injection.[3]
A 9-patient phase 2 trial of thymosin beta 4 eye drops for severe dry eye reported 35.1% less ocular discomfort than vehicle at day 56; the abstract describes eye drops, not TB-500.[1]
A second randomised trial of thymosin beta 4 solution in dry eye found no significant difference on either primary endpoint.[2]
What is missing for the blend
None of the 4 cached studies behind this page tested the three-part blend itself; they tested BPC-157 in rats, a TB500-sequence hydrogel and thymosin beta 4 eye drops separately; none tested GHK-Cu on the eye.
Calculated from cached studies 35052769, 41359360, 25826322, 26056426; studies of all three components together 0. Formula: count of cached studies testing GHK-Cu, BPC-157 and TB-500 together = 0
Other peptides people research for eyes
All peptides for eyes, comparedCommon questions
Does GLOW help with eyes?
The strongest study we summarise for eyes is human rct evidence, for an ingredient rather than the blend, across 4 studies with an outcome for eyes. A trial result is not an approval; see the legal status.
Is GLOW approved for eyes?
No. GLOW is not FDA approved for any use, including eyes.
What is the best peptide for eyes?
There is no single answer. Our eyes overview compares each candidate by evidence grade and legal status rather than by popularity.
Can GLOW peptide help your eyes?
The only human eye trials in the cached set used thymosin beta 4 eye drops, and one of them missed both primary endpoints.[2]
More on GLOW
Sources
- 1Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 2Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 3Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces · 2025PMID 41359360Accessed 2 Oct 2026
- 4Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.Biomedicines · 2021PMID 35052769Accessed 2 Oct 2026
- 5Official web pageOfficial web page · web page
Found an error? Report a correction.